Vectura results beat view; will up R&D by 10%
Inhaled-drug specialist Vectura Group posted a 29 percent rise in full-year revenue, helped by milestone payments from its partner Novartis, and said it had three new products in development. The British group is developing a generic steroid treatment for asthma and two speciality products: an inhaled anti-fungal treatment for lung-disease sufferers and a product to […]